Sepragen, a provider of process chromatography systems, has signed a letter of intent to acquire Cytobiologics. Assets include lab equipment and intellectual property related to certain rapid assays and a high-density bioreactor under development. The company plans to develop a cell culture/purification system. “The addition of Cytobiologics’ capability will provide us with facilities, talent and intellectual property to pursue the development of an integrated bio-manufacturing system,” said Depragen CEO Vinit Saxena.